Market Overview

NanoMedical Systems Receives $3M Grant to Advance nStrada™ Implantable Nanofluidics System for Long-Term Treatment of Opioid Use Disorder

Share:

AUSTIN, Texas, Aug. 14, 2018 (GLOBE NEWSWIRE) -- NanoMedical Systems, Inc. (NMS), an Austin-based company developing implantable, sustained-release, drug-delivery devices based on its nStrada™ nanofluidics platform has received a Fiscal Year 2017 Peer Reviewed Medical Research Program Award to advance the development of a combination product for the treatment of opioid use disorder.  The grant was awarded through the Congressionally Directed Medical Research Programs of the Department of Defense.  It provides $2,993,398 over three years to support formulation development, device development and manufacturing, preclinical studies, and initial human factors assessments in conjunction with the DeBakey VA Medical Center in Houston, Texas.

"We are pleased to partner with the DOD and the DeBakey VA Medical Center in support of our efforts to create an innovative product for the long-term treatment of opioid use disorder," said Dr. Yash Sabharwal, President & CEO of NanoMedical Systems, Inc. "The abuse of opioids is now recognized as a multi-billion-dollar national emergency and this funding will accelerate the development of a simple, but effective, solution for this significant patient and societal unmet need." 

About NanoMedical Systems

NanoMedical Systems develops novel drug-delivery devices based on its proprietary nStrada™ nanofluidics platform for sustained release (up to 6 months) of chronic therapies.  These devices can be loaded with a variety of drugs including small molecules, peptides, and proteins for subcutaneous implantation.  The nStrada™ devices rely on diffusion (passive or controlled) to achieve steady-state drug concentrations within a few days and then maintain constant release for the duration of the implant.  This performance represents a significant improvement over polymer-based implants and depots which suffer from an initial burst release and multiple weeks to achieve steady-state concentrations.  The nStrada™ platform is being used to develop a product for the sustained delivery of buprenorphine over many months with a constant release profile and no burst effect that can achieve the necessary drug concentration to be effective.  NanoMedical also partners with pharmaceutical companies providing custom-designed delivery devices based on the nStrada™ platform for their proprietary drugs. Products built on this platform have the potential to significantly improve patient access and adherence for a variety of critical therapies, improving outcomes and lowering costs. For more information, please visit www.nanomedsys.com.

Media Contact
Yash Sabharwal
President & CEO
NanoMedical Systems, Inc.
ysabharwal@nanomedsys.com
www.nanomedsys.com


View Comments and Join the Discussion!